Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2020-06-22 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
MATCHING HALT ENDS
Regulatory Filings Classification · 95% confidence The document text is extremely short (175 characters) and announces the end of a 'Matching halt' and the start of a 'Re-Opening Auction Call' on the Oslo Børs (Stock Exchange). This is a very specific, time-sensitive announcement related to trading suspension/resumption, which does not fit neatly into the defined categories like Earnings Release (ER), Annual Report (10-K), or Dividend Notice (DIV). Given the nature of a brief, non-standard regulatory market action announcement, the most appropriate fallback category is Regulatory Filings (RNS), as it covers general regulatory announcements that don't fit elsewhere.
2020-06-22 English
OSLO BØRS - MATCHING HALT
Regulatory Filings Classification · 95% confidence The document text is extremely short (117 characters) and announces a 'MATCHING HALT' by 'OSLO BØRS' due to investigation of share price movements. This is a specific, immediate regulatory action or announcement concerning trading activity, not a comprehensive financial report (like 10-K, IR) or a standard corporate disclosure (like ER, DIV). Since there is no specific category for trading halts, and it is a general regulatory announcement concerning market operations, the most appropriate fallback category is 'Regulatory Filings' (RNS).
2020-06-22 English
PCI Biotech: Minutes from Annual General Meeting 2020
AGM Information Classification · 99% confidence The document text is titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' (MINUTES FROM ORDINARY GENERAL MEETING) and details the proceedings, resolutions passed (including approval of the annual accounts and election of the board), and attendance records from a meeting held on May 27, 2020. This content directly corresponds to the documentation generated from an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2020-05-27 Norwegian
PCI Biotech: Minutes from Annual General Meeting 2020
AGM Information Classification · 98% confidence The document title explicitly states "Minutes from Annual General Meeting 2020". The text confirms that the Annual General Meeting took place and that the complete minutes are attached to the release. Since this document is very short (784 chars) and serves primarily to announce the availability of the minutes from the AGM, it fits the definition of AGM Information (AGM-R) better than a general Regulatory Filing (RNS). Although it mentions the minutes are attached, the core subject matter is the AGM proceedings.
2020-05-27 English
PCI Biotech: Disclosure of voting rights for Chairman of the Board
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Disclosure of voting rights for Chairman of the Board' and details the number of shares held and powers of attorney held by the chairman for the upcoming annual general meeting (AGM). This directly relates to the voting structure and representation at a shareholder meeting, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it discloses voting rights information, even if it's pre-meeting representation rather than post-meeting results. It is not a general director dealing (DIRS) as it focuses specifically on voting representation for the AGM, nor is it the AGM material itself (AGM-R). Given the focus on voting rights disclosure, DVA is the most precise fit.
2020-05-26 English
PCI Biotech: Notice of Annual General Meeting 2020
Board/Management Information Classification · 98% confidence The document is titled 'Innstilling fra Valgkomitéen' (Proposal from the Nomination Committee) of PCI Biotech Holding ASA, dated May 5, 2020. It details the committee's work, proposes the re-election of board members, suggests their remuneration, and also proposes remuneration for the nomination committee itself. This content directly relates to the composition and compensation of the Board of Directors and related governance bodies, which falls under the scope of Board/Management Information (MANG) or potentially Governance Information (CGR). However, the primary focus is on the proposal for board composition and remuneration ahead of a general meeting, which is a key component of management/board structure announcements. Given the options, MANG (Board/Management Information) is the most specific fit for proposals regarding board composition and director compensation.
2020-05-06 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.